Immunome (IMNM) Total Liabilities (2019 - 2026)

Immunome has reported Total Liabilities for 8 years, with the latest figure at $31.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 12.54% year-over-year to $31.1 million; the trailing twelve-month figure through Mar 2026 stood at $31.1 million (down 12.54% YoY), and the FY2025 full-year result was $48.8 million, down 17.32% from the prior year.
• Total Liabilities for Q1 2026 stood at $31.1 million, down from $48.8 million in the prior quarter.
• The five-year high for Total Liabilities was $87.1 million in Q3 2023, with the low at $7.4 million in Q4 2022.
• Historically, Total Liabilities has averaged $33.6 million across 5 years, with a median of $34.2 million in 2024.
• Annual changes were most pronounced in 2023 — Total Liabilities jumped 1067.05% — and 2024, when it tumbled 51.78%.
• Immunome's Total Liabilities stood at $7.4 million in 2022, then soared by 287.64% to $28.7 million in 2023, then jumped by 106.14% to $59.1 million in 2024, then slipped by 17.32% to $48.8 million in 2025, then tumbled by 36.32% to $31.1 million in 2026.
• The last three Total Liabilities figures came in at $31.1 million (Q1 2026), $48.8 million (Q4 2025), and $35.5 million (Q3 2025), per Business Quant data.